Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of COPD~* 10 pack-year or greater history of cigarette smoking~* Post-bronchodilator FEV1/FVC of \<0.7~* Predicted FEV1 of 70% of normal or less~* Modified Medical Research Council (mMRC) dyspnea score of 2 or greater~Exclusion Criteria:~* Women who are pregnant, lactating, or planning to become pregnant~* Respiratory disorders other than COPD, including a current diagnosis of asthma~* Clinically significant non-respiratory diseases or abnormalities that are not adequately controlled~* Significant allergy or hypersensitivity to anticholinergics, beta2-agonists, or the excipients of magnesium stereate or lactose used in the inhaler delivery device~* Hospitalization for COPD or pneumonia within 12 weeks prior to screening~* Lung volume reduction surgery within 12 weeks prior to screening~* Abnormal and clinically significant ECG findings at screening~* Clinically significant laboratory findings at screening~* Use of systemic corticosteroids, antibiotics for respiratory tract infections, high dose inhaled steroids (\>1000mcg fluticasone propionate or equivalent), PDE4 inhibitors, tiotropium, oral beta2-agoinists, short- and long-acting inhaled beta2-agonists, inhaled sodium cromoglycate or nedocromil sodium, or investigational medicines for defined time periods prior to the screening visit~* Use of long-term oxygen therapy (12 hours or greater per day)~* Regular use of nebulized treatment with short-acting bronchodilators~* Participation in the acute phase of a pulmonary rehabilitation program~* A know or suspected history of alcohol or drug abuse~* Affiliation with the investigational site~* Previous use of GSK573719 or the combination of GSK573719/GW642444

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GSK573719 (Type: EXPERIMENTAL): active drug
- Placebo (Type: PLACEBO_COMPARATOR): no active drug

Based on this trial design, predict the completion outcome and termination type (if applicable).